Cytomegalovirus Viral Load Threshold to Guide Preemptive Therapy in Hematopoietic Cell Transplant Recipients: Correlation with CMV Disease.
Alicja Sadowska-KlasaWendy M LeisenringAjit P LimayeMichael BoeckhPublished in: The Journal of infectious diseases (2023)
A systematic review of recent randomized and observational studies demonstrated that antiviral preemptive therapy started at cytomegalovirus (CMV) viral load thresholds between 2 and 3 log10 IU/mL were associated with similar CMV disease rates. Thus, viral thresholds in this range appear to effectively protect patients not receiving prophylaxis.
Keyphrases
- end stage renal disease
- epstein barr virus
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cell therapy
- sars cov
- open label
- prognostic factors
- peritoneal dialysis
- double blind
- bone marrow
- single cell
- randomized controlled trial
- clinical trial
- phase iii
- mesenchymal stem cells
- patient reported
- smoking cessation